Cargando…
Predicting survival in metastatic non‐small cell lung cancer patients with poor ECOG‐PS: A single‐arm prospective study
BACKGROUND: Patients with advanced non‐small cell lung cancer (NSCLC) are a heterogeneous population with short lifespan. We aimed to develop methods to better differentiate patients whose survival was >90 days. METHODS: We evaluated 83 characteristics of 106 treatment‐naïve, stage IV NSCLC patie...
Autores principales: | Cunha, Mateus Trinconi, de Souza Borges, Ana Paula, Carvalho Jardim, Vinicius, Fujita, André, de Castro, Gilberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972023/ https://www.ncbi.nlm.nih.gov/pubmed/36161783 http://dx.doi.org/10.1002/cam4.5254 |
Ejemplares similares
-
Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
por: Cunha, Mateus Trinconi, et al.
Publicado: (2021) -
Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1
por: Caires-Lima, Rafael, et al.
Publicado: (2018) -
Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2
por: Mojsak, Damian, et al.
Publicado: (2021) -
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
por: Schneider, B P, et al.
Publicado: (2014) -
Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients
por: Kinker, Gabriela Sarti, et al.
Publicado: (2016)